סרקוואל

האם התרופה סרקוואל במינון של 300 מג יכולה לגרום להופעה של אקנה בפנים? האם אולי היא מעלה את הורמון הפרולקטין?

שלום שירה, 1) אקנה מוזכרת ספוראדית כאשר הקשר לא ברור בין התרופה לתופעה. 2) לגבי הפרולקטין מדווח שכאשר מטופלים עם סכיזופרניה נוטלים סרוקוול (quetiapine) רמת פרולקטין שנמצאה כמוגברת בחולים לא מעטים יורדת לנורמה בתוך פרק זמן. ניתן לקרוא על כך בתקציר כאן: J Psychopharmacol. 2009 Feb 24. [Epub ahead of print] LinksComparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. Bushe C, Sniadecki J, Bradley A, Poole Hoffmann V. Eli Lilly and Company, Basingstoke, UK. AbstractSchizophrenia patients have a potential increased risk of metabolic dysregulation during antipsychotic treatments. Our objective was to compare changes in prolactin and metabolic variables (glucose, lipids and weight) as a post-hoc analysis from a six-month, randomised, controlled study of olanzapine (OLZ, n = 171; 10-20 mg/day) or quetiapine (QUE, n = 175; 300-700 mg/day). No statistically significant treatment group differences for baseline to endpoint mean changes in body mass index (P = 0.209) or weight (P = 0.250) were observed. There was a greater incidence of clinically significant weight gain (defined as >/=7% increase from baseline) in OLZ (19.2%) compared to QUE (13.2%)-treated patients (P = 0.181). No statistically significant treatment group differences for lipids and glucose variables, either as mean change from baseline to endpoint or treatment-emergent (TE) categorical changes were found (P >/= 0.05). Incidence rates for TE diabetes were similar between treatment groups 2.5% (n = 4) in the OLZ-treatment group and 1.3% (n = 2) in the QUE-treatment group (P = 0.685). Hyperprolactinaemia was present at baseline in many patients (OLZ 32.9%; QUE 31.4%), but after 2 weeks of treatment prolactin values had reverted to normal for nearly all patients (OLZ 100%; QUE 99.4%). There were no significant treatment differences in any variable between cohorts. שנה טובה